Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

US Patent 11285209 · Granted Mar 29, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CTLA-4 antibodies and methods of use thereof2025
Anti-CTLA-4 antibodies and methods of use thereof2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Imaging systems and methods2025
Hybrid nail gun2025
Neoantigens and uses thereof for treating cancer2025
Neoantigens and uses thereof for treating cancer2025